Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1948 1
1964 3
1965 19
1966 56
1967 86
1968 95
1969 90
1970 129
1971 127
1972 122
1973 111
1974 100
1975 119
1976 86
1977 105
1978 103
1979 92
1980 79
1981 84
1982 88
1983 86
1984 80
1985 94
1986 121
1987 215
1988 204
1989 208
1990 282
1991 324
1992 291
1993 357
1994 365
1995 357
1996 363
1997 395
1998 434
1999 419
2000 506
2001 565
2002 621
2003 663
2004 678
2005 731
2006 871
2007 885
2008 913
2009 915
2010 1031
2011 1096
2012 1181
2013 1142
2014 1242
2015 1227
2016 1127
2017 1079
2018 980
2019 501
2020 19
Text availability
Article attribute
Article type
Publication date

Search Results

22,238 results
Results by year
Filters applied: . Clear all
Page 1
A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma.
Witzig TE, et al. Ann Oncol 2015 - Review. PMID 25712458 Free article.
Lenalidomide is an oral non-chemotherapy immunomodulator with direct and indirect effects on non-Hodgkin lymphoma (NHL) cells and with single-agent activity in relapsed/refractory aggressive and indolent B-cell NHL, including mantle cell lymphoma (MCL), diffuse large B-cell lymphoma, and follicular lymphoma. ...
Lenalidomide is an oral non-chemotherapy immunomodulator with direct and indirect effects on non-Hodgkin lymphoma (NHL) cells and wit …
Treatment of HIV-Associated Lymphomas: The Latest Approaches for Optimizing Outcomes
Hunter NB, et al. Oncology (Williston Park) 2017 - Review. PMID 29297171 Free article.
Treatment outcomes for patients with HIV-related lymphoma have improved since the advent of combination antiretroviral therapy. Standard regimens, including intensive regimens, are being used with encouraging results in patients with diffuse large B-cell lymphoma, Burkitt lymphoma, Hodgkin lymphoma, and primary central nervous system lymphoma. ...
Treatment outcomes for patients with HIV-related lymphoma have improved since the advent of combination antiretroviral therapy. Stand …
Targeting B-cell non Hodgkin lymphoma: New and old tricks.
Solimando AG, et al. Leuk Res 2016 - Review. PMID 26818572
In the past years, rituximab (anti-CD20) emerged as the standard of care in the induction treatment of follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), chronic lymphocytic leukemia (CLL), and mantle cell lymphoma (MCL), as well as in other subsets. Since the benefits of immuno-chemotherapy have been clearly demonstrated in a whole range of lymphomas, several innovative approaches are being explored to achieve significant responses, particularly in refractory B-cell non-Hodgkin lymphoma (NHL) cases. ...
In the past years, rituximab (anti-CD20) emerged as the standard of care in the induction treatment of follicular lymphoma (FL), diff …
Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma.
Younes A, et al. Haematologica 2017 - Clinical Trial. PMID 28971900 Free PMC article.
Overall, 72 patients (26 with diffuse large B-cell lymphoma, 22 with mantle cell lymphoma, and 24 with follicular lymphoma) were treated. The overall response rates were 11.5%, 22.7%, and 25.0% in patients with diffuse large B-cell lymphoma, mantle cell lymphoma, and follicular lymphoma, respectively; two patients (one each with diffuse large B-cell lymphoma and mantle cell lymphoma) achieved a complete response. ...
Overall, 72 patients (26 with diffuse large B-cell lymphoma, 22 with mantle cell lymphoma, and 24 with follicular lymphoma
A review of rituximab, the first anti-CD20 monoclonal antibody used in the treatment of B non-Hodgkin's lymphomas
Feugier P. Future Oncol 2015 - Review. PMID 25952779
In combination with chemotherapy, it has significantly improved response rates and progression-free survival and, for some of them, overall survival of patients with diffuse large B-cell lymphoma, follicular lymphoma, marginal zone lymphoma, mantle cell lymphoma. Moreover, it has been shown to improve progression-free survival in maintenance in follicular lymphoma as well as mantle cell lymphoma. ...
In combination with chemotherapy, it has significantly improved response rates and progression-free survival and, for some of them, overall …
Recent molecular and therapeutic advances in B-cell non-Hodgkin lymphoma in children.
Giulino-Roth L and Goldman S. Br J Haematol 2016 - Review. PMID 26996160
Paediatric B-cell non-Hodgkin lymphoma (B-NHL) compromises a heterogeneous group of histological entities of which Burkitt lymphoma is the most common. ...
Paediatric B-cell non-Hodgkin lymphoma (B-NHL) compromises a heterogeneous group of histological entities of which Burkitt lymphom
Blinatumomab: a historical perspective
Nagorsen D, et al. Pharmacol Ther 2012 - Review. PMID 22940266
Here, we review how blinatumomab has so far been pre-clinically and clinically developed for the treatment of patients with non-Hodgkin's lymphoma and acute lymphoblastic leukemia....
Here, we review how blinatumomab has so far been pre-clinically and clinically developed for the treatment of patients with non-Hodgkin's …
22,238 results
Jump to page
Feedback